Short Seller Alleges Praxis Precision's Potential $3 Billion Drug 'A House Of Cards' - Praxis Precision Medicine ( NASDAQ:PRAX )
A short seller is challenging Praxis Precision Medicines Inc. ( NASDAQ:PRAX ) after the company claimed success from its Phase 3 trial of ulixacaltamide. Culper Research report argues that the data underpinning its essential tremor program cannot withstand regulatory scrutiny.
Behind the Scenes of Praxis Precision Medicine's Latest Options Trends - Praxis Precision Medicine ( NASDAQ:PRAX )
Whales with a lot of money to spend have taken a noticeably bearish stance on Praxis Precision Medicine. Looking at options history for Praxis Precision Medicine ( NASDAQ:PRAX ) we detected 8 trades.
Praxis Precision Medicine's Options Frenzy: What You Need to Know - Praxis Precision Medicine ( NASDAQ:PRAX )
Whales with a lot of money to spend have taken a noticeably bearish stance on Praxis Precision Medicine. Looking at options history for Praxis Precision Medicine ( NASDAQ:PRAX ) we detected 8 trades.
Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session - ALPS Group ( NASDAQ:ALPS ) , Alvotech ( NASDAQ:ALVO )
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining more than 100 points on Monday. Shares of Kimberly-Clark Corporation ( NYSE:KMB ) fell sharply in pre-market trading after the company announced it will acquire Kenvue in a cash and stock transaction with an enterprise ...
Praxis Precision Medicines, Inc. ( PRAX ) Expected to Beat Earnings Estimates: Should You Buy?
Praxis Precision Medicines (PRAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Meet the Biotech Stock That Just Jumped 251% Higher
Find out what sent this typically overlooked stock through the roof.
Revolution Medicines, Disc Medicine, American Express And Other Big Stocks Moving Higher On Friday - American Express ( NYSE:AXP ) , AppFolio ( NASDAQ:APPF )
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Friday.
Praxis Precision Medicines ( PRAX ) Surges 183.7%: Is This an Indication of Further Gains?
Praxis Precision Medicines (PRAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why CSX Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket - American Battery Tech ( NASDAQ:ABAT ) , Achieve Life Sciences ( NASDAQ:ACHV )
Shares of CSX Corp ( NASDAQ:CSX ) rose sharply in pre-market trading after the company posted better-than-expected results for the third quarter. CSX reported third-quarter revenue of $3.59 billion, beating analyst estimates of $3.58, according to Benzinga Pro.
Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering
BOSTON, Oct. 16, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc. ( NASDAQ: PRAX ) , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ( CNS ) disorders characterized by neuronal excitation-inhibition ...
Dow Dips Over 100 Points; US Crude Oil Inventories Surge - Hyperfine ( NASDAQ:HYPR ) , JB Hunt Transport Servs ( NASDAQ:JBHT )
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.30% to 46,113.98 while the NASDAQ slipped 0.21% to 22,622.73. The S&P 500 also fell, dropping, 0.34% to 6,648.52. Real estate shares jumped by 0.5% on Thursday.
Enerpac Tool Group Posts Upbeat Results, Joins Praxis Precision Medicines, J B Hunt, Salesforce And Other Big Stocks Moving Higher On Thursday - Cellectis ( NASDAQ:CLLS ) , Salesforce ( NYSE:CRM )
U.S. stocks were higher, with the Nasdaq Composite gaining more than 50 points on Thursday. Shares of Enerpac Tool Group Corp ( NYSE:EPAC ) rose sharply during Thursday's session following better-than-expected fourth-quarter results.
Dow Surges Over 100 Points; Charles Schwab Posts Upbeat Earnings - Hyperfine ( NASDAQ:HYPR ) , Mira Pharmaceuticals ( NASDAQ:MIRA )
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.34% to 46,412.27 while the NASDAQ climbed 0.73% to 22,834.55. The S&P 500 also rose, gaining, 0.41% to 6,698.54.
Why Is Praxis Precision Medicines Stock Soaring Today - Praxis Precision Medicine ( NASDAQ:PRAX )
Praxis Precision Medicines Inc. ( NASDAQ:PRAX ) stock skyrocketed on Thursday. PRAX is reaching significant price levels. Check the market position here. The clinical-stage biopharmaceutical company released topline results for the Phase 3 Essential3 program of ulixacaltamide in essential ...
Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor - Praxis Precision Medicine ( NASDAQ:PRAX )
Patients treated with ulixacaltamide in the parallel-group study ( Study 1 ) showed a mean improvement from baseline in the Modified Activities of Daily Living 11 at Week 8, the pre-specified primary endpoint, of 4.3 points ( p<0.0001 )
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets
BOSTON, Oct. 09, 2025 ( GLOBE NEWSWIRE ) -- Pyxis Oncology, Inc. ( Nasdaq: PYXS ) , a clinical-stage company developing antibody-drug conjugate ( ADC ) therapeutics for difficult-to-treat cancers, today announced the appointment of Alex Kane, MBA, as Senior Vice President, Investor Relations & ...
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - Pyxis Oncology ( NASDAQ:PYXS )
BOSTON, Oct. 09, 2025 ( GLOBE NEWSWIRE ) -- Pyxis Oncology, Inc. ( NASDAQ:PYXS ) , a clinical-stage company developing antibody-drug conjugate ( ADC ) therapeutics for difficult-to-treat cancers, today announced the appointment of Alex Kane, MBA, as Senior Vice President, Investor Relations & ...
PRAXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Praxis Precision Medicines, Inc. on Behalf of Praxis Stockholders and Encourages Investors to Contact the Firm - Praxis Precision Medicine ( NASDAQ:PRAX )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Praxis ( PRAX ) To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Is Investigating Praxis, Align, Lantheus, and Spirit and Encourages Investors to Contact the Firm - ( FLYY ) , Align Technology ( NASDAQ:ALGN )
NEW YORK, Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Praxis Precision Medicines, Inc. PRAX, Align Technology, Inc. ALGN, Lantheus Holdings, Inc. LNTH, and Spirit Aviation ...
Praxis Precision Medicines to Participate in Upcoming Fireside Chat - Praxis Precision Medicine ( NASDAQ:PRAX )
BOSTON, Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc.
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
BOSTON, Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc. ( NASDAQ: PRAX ) , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ( CNS ) disorders characterized by neuronal excitation-inhibition ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX - Praxis Precision Medicine ( NASDAQ:PRAX )
NEW YORK, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. ( "Praxis" or the "Company" ) PRAX. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
PRAXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Praxis Precision Medicines, Inc. on Behalf of Praxis Stockholders and Encourages Investors to Contact the Firm - Praxis Precision Medicine ( NASDAQ:PRAX )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Praxis ( PRAX ) To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX - Praxis Precision Medicine ( NASDAQ:PRAX )
NEW YORK, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. ( "Praxis" or the "Company" ) PRAX. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX - Praxis Precision Medicine ( NASDAQ:PRAX )
NEW YORK, Aug. 09, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. ( "Praxis" or the "Company" ) PRAX. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
BOSTON, Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc. ( NASDAQ: PRAX ) , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ( CNS ) disorders characterized by neuronal excitation-inhibition ...
Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm - Praxis Precision Medicine ( NASDAQ:PRAX )
Investors can contact the law firm at no cost to learn more about recovering their losses
Praxis Precision Medicines to Participate in Upcoming Fireside Chat - Praxis Precision Medicine ( NASDAQ:PRAX )
BOSTON, Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc.
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
BOSTON, Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc. ( NASDAQ: PRAX ) , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ( CNS ) disorders characterized by neuronal excitation-inhibition ...
What's Going On With Praxis Precision Medicines Stock Monday? - Praxis Precision Medicine ( NASDAQ:PRAX )
Vormatrigine led to a 56.3% median seizure reduction; 22% had complete seizure control in the final month. 23% of patients discontinued the trial; most adverse events were mild to moderate. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
Praxis ( PRAX ) Q2 Loss Widens 90%
Praxis Precision Medicines ( NASDAQ:PRAX ) is a clinical-stage biopharmaceutical company specializing in therapies for central nervous system ( CNS ) disorders. On August 4, 2025, it reported financial results for Q2 FY2025. The most notable news from the release was widening operational losses ( ...
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BOSTON, July 02, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc. ( Nasdaq: PRAX ) , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ( CNS ) disorders characterized by neuronal excitation-inhibition ...
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BOSTON, June 04, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc. ( Nasdaq: PRAX ) , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ( CNS ) disorders characterized by neuronal excitation-inhibition ...
Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside - Praxis Precision Medicine ( NASDAQ:PRAX )
Praxis had $472 million in cash as of March 31, expected to fund operations into 2028. Vormatrigine may reach over $1 billion in peak sales for major epilepsy indications. Feel unsure about the market's next move? Copy trade alerts from Matt Maley-a Wall Street veteran who consistently finds ...
This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Republic Services ( NYSE:RSG ) , Praxis Precision Medicine ( NASDAQ:PRAX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Seaport Global analyst John Mazzoni initiated coverage on Waste Management, Inc.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BOSTON, May 02, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc. ( Nasdaq: PRAX ) , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ( CNS ) disorders characterized by neuronal excitation-inhibition ...
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Praxis Precision Medicine ( NASDAQ:PRAX )
BOSTON, May 02, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc.
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results
On track for six major study readouts across four programs over the next 12 months ...
Praxis Precision Medicines to Participate in Upcoming April Conferences - Praxis Precision Medicine ( NASDAQ:PRAX )
BOSTON, April 03, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc.
Praxis Precision Medicines to Participate in Upcoming April Conferences
BOSTON, April 03, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc. ( NASDAQ: PRAX ) , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ( CNS ) disorders characterized by neuronal excitation-inhibition ...
Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting - Ionis Pharmaceuticals ( NASDAQ:IONS ) , Praxis Precision Medicine ( NASDAQ:PRAX )
BOSTON, March 24, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc.
Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting
BOSTON, March 24, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc. ( NASDAQ: PRAX ) , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ( CNS ) disorders characterized by neuronal excitation-inhibition ...
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BOSTON, March 04, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc. ( Nasdaq: PRAX ) , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ( CNS ) disorders characterized by neuronal excitation-inhibition ...
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Praxis Precision Medicine ( NASDAQ:PRAX )
BOSTON, March 04, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc.
Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate - Praxis Precision Medicine ( NASDAQ:PRAX )
Praxis' Essential Tremor study halted after interim data failed to meet efficacy goals. Company holds $469.5 million in cash, funding operations into 2028. Our government trade tracker caught Pelosi's 169% AI winner. Discover how to track all 535 Congress member stock trades today.
Market Whales and Their Recent Bets on PRAX Options - Praxis Precision Medicine ( NASDAQ:PRAX )
Whales with a lot of money to spend have taken a noticeably bearish stance on Praxis Precision Medicine. Looking at options history for Praxis Precision Medicine PRAX we detected 39 trades.
Praxis Precision Medicines, Inc. ( PRAX ) Reports Q4 Loss, Tops Revenue Estimates
Praxis Precision Medicines (PRAX) delivered earnings and revenue surprises of 0.68% and 1,467.86%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Praxis Precision Medicines Provides Update on Essential3 and Corporate Update
BOSTON, Feb. 28, 2025 ( GLOBE NEWSWIRE ) -- Praxis Precision Medicines, Inc. ( NASDAQ: PRAX ) , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system ( CNS ) disorders characterized by neuronal excitation-inhibition ...
IGM Biosciences, Inc. ( IGMS ) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
IGM Biosciences (IGMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Praxis Precision Medicines, Inc. ( PRAX ) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Praxis Precision Medicines (PRAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
